861 related articles for article (PubMed ID: 21443475)
21. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
[TBL] [Abstract][Full Text] [Related]
22. Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments.
Yu HP; Aljuffali IA; Fang JY
Curr Pharm Des; 2017; 23(3):481-494. PubMed ID: 28292243
[TBL] [Abstract][Full Text] [Related]
23. Targeting of nanoparticles in cancer: drug delivery and diagnostics.
Talekar M; Kendall J; Denny W; Garg S
Anticancer Drugs; 2011 Nov; 22(10):949-62. PubMed ID: 21970851
[TBL] [Abstract][Full Text] [Related]
24. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
25. Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer efficacy.
Lin X; Gao R; Zhang Y; Qi N; Zhang Y; Zhang K; He H; Tang X
Expert Opin Drug Deliv; 2012 Jul; 9(7):767-81. PubMed ID: 22554018
[TBL] [Abstract][Full Text] [Related]
26. PCL/PEG copolymeric nanoparticles: potential nanoplatforms for anticancer agent delivery.
Gou M; Wei X; Men K; Wang B; Luo F; Zhao X; Wei Y; Qian Z
Curr Drug Targets; 2011 Jul; 12(8):1131-50. PubMed ID: 21443476
[TBL] [Abstract][Full Text] [Related]
27. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
28. Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors.
Jiang H; Geng D; Liu H; Li Z; Cao J
Drug Deliv; 2016 Nov; 23(9):3665-3673. PubMed ID: 27749102
[TBL] [Abstract][Full Text] [Related]
29. Nanomedicine for Treatment of Lung Cancer.
Hussain S
Adv Exp Med Biol; 2016; 890():137-47. PubMed ID: 26703803
[TBL] [Abstract][Full Text] [Related]
30. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles.
Wong HL; Bendayan R; Rauth AM; Li Y; Wu XY
Adv Drug Deliv Rev; 2007 Jul; 59(6):491-504. PubMed ID: 17532091
[TBL] [Abstract][Full Text] [Related]
32. Lipid-coated polymeric nanoparticles for cancer drug delivery.
Krishnamurthy S; Vaiyapuri R; Zhang L; Chan JM
Biomater Sci; 2015 Jul; 3(7):923-36. PubMed ID: 26221931
[TBL] [Abstract][Full Text] [Related]
33. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
[TBL] [Abstract][Full Text] [Related]
34. What does the future hold for chemotherapy with the use of lipid-based nanocarriers?
Pucci C; Martinelli C; Ciofani G
Future Oncol; 2020 Feb; 16(5):81-84. PubMed ID: 31872773
[No Abstract] [Full Text] [Related]
35. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
Beretta GL; Cavalieri F
Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
[TBL] [Abstract][Full Text] [Related]
36. DePEGylation strategies to increase cancer nanomedicine efficacy.
Kong L; Campbell F; Kros A
Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
[TBL] [Abstract][Full Text] [Related]
37. Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application.
Rizwanullah M; Ahmad MZ; Garg A; Ahmad J
Biochim Biophys Acta Gen Subj; 2021 Sep; 1865(9):129936. PubMed ID: 34058266
[TBL] [Abstract][Full Text] [Related]
38. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
39. Oral lipid nanomedicines: Current status and future perspectives in cancer treatment.
El Moukhtari SH; Rodríguez-Nogales C; Blanco-Prieto MJ
Adv Drug Deliv Rev; 2021 Jun; 173():238-251. PubMed ID: 33774117
[TBL] [Abstract][Full Text] [Related]
40. The suitability of liposomes for the delivery of hydrophobic drugs - A case study with curcumin.
Kolter M; Wittmann M; Köll-Weber M; Süss R
Eur J Pharm Biopharm; 2019 Jul; 140():20-28. PubMed ID: 31015019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
